Efficacy of cancer gene therapy in aging adenocarcinoma cells engineered to release IL-2 are rejected but do not induce tumor specific immune memory in old mice

Gene Therapy

Volumn 7, Issue 7, 2000, Pages 624-632

  Provinciali, M ^a   Argentati, K ^a   Tibaldi, A ^a  

^a INRCA   (Italy)

Author keywords

Aging; Cancer; Gene therapy; Immune memory; Mice

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; INTERLEUKIN 2;

ADENOCARCINOMA; AGING; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER; CARCINOMA CELL; CELL INFILTRATION; CELL TRANSPLANTATION; CONTROLLED STUDY; GENE THERAPY; GENETIC ENGINEERING; IMMUNE RESPONSE; IMMUNOLOGICAL MEMORY; MACROPHAGE; MALE; MOUSE; NEUTROPHIL; NONHUMAN; ORGAN TRANSPLANTATION; PRIORITY JOURNAL; PROVOCATION TEST; T LYMPHOCYTE; THYMUS;

ADENOCARCINOMA; ADOPTIVE TRANSFER; AGING; ANIMALS; APOPTOSIS; GENE THERAPY; IMMUNOLOGIC MEMORY; IMMUNOTHERAPY; IN SITU NICK-END LABELING; INTERLEUKIN-2; MALE; MICE; MICE, INBRED BALB C; T-LYMPHOCYTES, CYTOTOXIC; THYMUS GLAND; TRANSFECTION;

ANIMALIA;

EID: 0034066895     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301131     Document Type: Article

References (34)

1. Patel PM, Collins MKL. Gene therapy. In: Gore M, Riches P (eds). Immunotherapy in Cancer. John Wiley: Chichester, 1996, pp 221-234.
2. Colombo MP, Forni G. Cytokine gene transfer in tumor inhibition and tumor therapy: where are we now? Immunol Today 1994; 15: 48-51.
3. Dranoff G, Mulligan RC. Gene transfer as cancer therapy. Adv Immunol 1995; 58: 417-454.
4. Roth JA, Cristiano RJ. Gene therapy for cancer: what have we done and where are we going? J Natl Cancer Inst 1997; 88: 21-39.
5. Musiani P et al. Cytokines, tumor-cell death and immunogenicity: a question of choice. Immunol Today 1997; 18: 32-36.
6. Cavallo F et al. Protective and curative potential with interleukin-2-gene-transfected cells from a spontaneous mouse mammary adenocarcinoma. Cancer Res 1993; 53: 5067-5070.
7. Cavallo F et al. Antitumor efficacy of adenocarcinoma cells engineered to produce interleukin-12 (IL-12) or other cytokines compared with exogenous IL-12. J Natl Cancer Inst 1997; 89: 1049-1058.
8. + T lymphocytes in the mammary and memory response to nonimmunogenic murine mammary adenocarcinoma made immunogenic by IL-2 gene. J Immunol 1992; 149: 3627-3635.
9. Miller RA. The aging immune system: primer and prospectus. Science 1996; 273: 70-74.
10. Fabris N, Mocchegiani E, Provinciali M. Plasticity of neuroendocrine-thymus interactions during aging. Exp Gerontol 1997; 32: 415-430.
11. Pawelec G, Solana R. Immunosenescence. Immunol Today 1997; 18: 514-516.
12. George AJT, Ritter MA. Thymic involution with ageing: obsolescence or good housekeeping? Immunol Today 1996; 17: 267-272.
13. Thoman ML, Weigle WO. The cellular and subcellular bases of immunosenescence. Adv Immunol 1989; 46: 221-261.
14. Proust JJ, Bender BS, Nagel JE, Adler WH. Developmental biology and senescence. In: Nelson DS (ed). Natural Immunity. Academic Press: Australia, 1989, pp 392-439.
15. Provinciali M, Di Stefano G, Fabris N. Evaluation of LAK cell development in young and old healthy humans. Nat Immunity 1995; 14: 134-144.
16. Provinciali M, Di Stefano G, Stronati S, Fabris N. Generation of human lymphokine-activated killer cells following an IL-2 pulse in elderly cancer patients. Cytokine 1998; 10: 132-139.
17. Rosen ST, Benson III AB, Kuzel T, Tallman MS. Biologic therapies in cancer patients: inplications for treatment in older patients. In: Balducci L, Lyman GH, Ershler WB (eds). Geriatric Oncology. Lippincott: Philadelphia, 1992, pp 181-189.
18. Smith KA. Interleukin-2. Ann Rev Immunol 1984; 2: 319-335.
19. Henney CS, Kuribayashi DE, Kern E, Gillis S. Interleukin-2 augments natural killer activity. Nature 1981; 291: 335-338.
20. Grimm EA, Rosenberg SA. The human lymphokine activated killer cell phenomenon. Lymphokines 1983; 9: 435-438.
21. Espinoza-Delgado I et al. Expression and role of p75 interleukin 2 receptor on human monocytes. J Exp Mol 1990; 171: 1821-1826.
22. Phalavani MA, Richardson AR. The effect of age on the expression of interleukin-2. Mech Ageing Dev 1996; 89: 125-154.
23. Provinciali M et al. Adjuvant effect of low-dose interleukin-2 on antibody response to influenza virus vaccination in healthy elderly subjects. Mech Ageing Dev 1994; 77: 75-82.
24. Saini A, Sei Y. Age-related impairment of early and late events of signal transduction in mouse immune cells. Life Sci 1993; 52: 1759-1765.
25. − T cells with aging. Mech Ageing Dev 1997; 94: 123-134.
26. Hirokawa K, Utsuyama M. The effect of sequential multiple grafting of syngeneic newborn thymus on the immune functions and life expectancy of aging mice. Mech Ageing Dev 1984; 28: 111-121.
27. Butenko GM, Kharazi AI. Effect of thymus grafts of various ages on the immune system formation in CBA mice. Mech Ageing Dev 1985; 30: 227-237.
28. Garg M, Luo W, Kaplan AM, Bondada S. Cellular basis of decreased immune responses to pneumococcical vaccines in aged mice. Infect Immun 1996; 64: 4456-4462.
29. Vetvicka V, Tlaskalova-Hogenova H, Pospisil M. Impaired antigen presenting function of macrophages from aged mice. Immunol Invest 1985; 14: 105-114.
30. Albert ML, Sauter B, Bahrdwaj N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 1998; 392: 86-89.
31. Henry F et al. Antigen-presenting cells that phagocytose apoptotic tumor-derived cells are potent tumor vaccines. Cancer Res 1999; 59: 3329-3332.
32. Nanni P et al. TS/A: a new metastasizing cell line from a BALB/c spontaneous mammary adenocarcinoma. Clin Exp Metast 1983; 1: 373-380.
33. Bryant J, Day R, Whitside T, Herberman RB. Calculation of lytic units for the expression of cell-mediated cytotoxicity. J Immunol Meth 1992; 146: 91-103.
34. Basso A, Piantanelli L, Rossolini G, Roth GS. Reduced DNA synthesis in primary cultures of hepatocytes from old mice is restored by thymus grafts. J Gerontol 1998; 53A: B111-B116.